| ACM arm (clusters, n = 7) | TTR-only arm (clusters, n = 7) | Crude ACM-TTR difference (95% CI); P valuea | Adjusted ACM-TTR difference (95% CI); P valuea | |
|---|---|---|---|---|
| Mean outcome (95% CI)b | ||||
| Primary outcome | ||||
| Change in HbA1c (pp)c | -2.26pp (-2.99 to -1.53) | -1.44pp (-2.34 to -0.54) | -0.82pp (-1.86 to 0.21); 0.11 | -0.57pp (-1.44 to 0.29); 0.17 |
| Secondary outcomes | ||||
| Adherenced | 75.64% (45.56 to 105.71%) | 36.29% (3.9 to 68.67%) | 39.35pp (-0.02 to 78.73); 0.0501 | 36.06pp (-0.78 to 72.9); 0.054 |
| Glycaemic controle | 45.04% (32.48 to 57.6%) | 34.86% (16.15 to 53.57%) | 10.18pp (-10.21 to 30.57); 0.29 | 10.87pp (-7.92 to 29.67); 0.23 |
| Change in SBP (mmHg)c | 2.33 (-0.1 to 4.76) | 1.47 (-4.32 to 7.26) | 0.86 (-5.05 to 6.77); 0.75 | 1.3 (-3.41 to 6.01); 0.56 |
| Change in DBP (mm Hg)c | 2.81 (-1.04 to 6.66) | 0.68 (-4.34 to 5.69) | 2.13 (-3.54 to 7.81); 0.43 | 0.29 (-1.93 to 2.51); 0.78 |
| Hypertension controlf | 73.2% (61.92 to 84.49%) | 72.47% (59.36 to 85.58%) | 0.73pp (-14.71 to 16.17); 0.92 | 0.0pp (-12 to 12.95); 0.93 |
| Change in total serum cholesterol (mg/dL)c | -5.24 (-19.82 to 9.34) | 2.75 (-5.73 to 11.22) | -7.99 (-23.43 to 7.45); 0.27 | -5.79 (-20.22 to 8.65); 0.4 |
ACM = additional case management. CI = confidence intervals. TTR = test, treat, and record. PP = percentage points.
aAll ACM–TTR differences (that is, ACM effect size measures) are based on analysis of cluster-level (mean/proportion) outcomes. bMean outcomes and their 95% confidence intervals are based on cluster-level (mean/proportion) raw outcome data. cAll change outcomes are calculated as outcome at 9 months minus outcome at baseline. dAdherence defined as attendance of ≥4 follow-up appointments within 9 months. eGlycaemic control defined as 9-month HbA1c (%) <7%. fHypertension control defined as 9-month systolic blood pressure ≤140 mmHg.
All analyses exclude patients’ missing outcome and/or covariate data as required by the relevant analysis.